SP-8356

SP-8356 is a synthetic small molecule derived from (1S)-(–)-verbenone and functions as a potent and orally active inhibitor of CD147, also known as basigin or extracellular matrix metalloproteinase inducer (EMMPRIN). It disrupts the interaction between CD147 and cyclophilin A (CypA), which plays a key role in promoting plaque rupture in atherosclerosis by activating matrix metalloproteinases such as MMP-9. Preclinical studies have demonstrated that SP-8356 suppresses plaque development, improves plaque stability by reducing necrotic lipid core size, suppressing macrophage infiltration, enhancing fibrous cap thickness via increased vascular smooth muscle cell content, and attenuates MMP activity. Additionally, it has shown anti-inflammatory effects in cancer models by inhibiting NF-kB signaling and inducing apoptosis through p53 accumulation via inhibition of its negative regulator MDM2. The drug is being developed primarily for cardiovascular diseases such as atherosclerosis but has also shown preclinical efficacy against various cancers including breast cancer and non-small cell lung cancer[1][2][4][5][6].

Other names

(1S,5R)-4-(3,4-dihydroxy-5-methoxystyryl)-6,6-dimethylbicyclo[3.1.1]hept-3-en-2-one(1S)-(–)-verbenone derivative